Traders discuss if CBD is just smoke and mirrors after the first FDA meeting on the trend

The FDA meets on CBD regulation. The impact on pot stocks, with CNBC’s Aditi Roy and Melissa Lee, and the Fast Money traders, Carter Worth, Tim Seymour, …


  1. Perhaps JAMA will wake them up…. then there is the fact that cannabinoids are being used in conjunction with chemo for several different cancers, phase II trials since phase I was so promising.

    Original Investigation
    August 29, 2018
    Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis
    A Randomized Clinical Trial
    Sagnik Bhattacharyya, MBBS, MD, PhD1; Robin Wilson, MBBS, MRCPsych1; Elizabeth Appiah-Kusi, MSc1; et al Aisling O’Neill, MSc1; Michael Brammer, PhD2; Jesus Perez, MBBS, MD, PhD3; Robin Murray, DSc, FRCPsych, FRS1; Paul Allen, PhD1,4; Matthijs G. Bossong, PhD1,5; Philip McGuire, MD, PhD, FRCPsych1
    Author Affiliations
    JAMA Psychiatry. Published online August 29, 2018. doi:10.1001/jamapsychiatry.2018.2309

    Results  Of the 16 participants in the CBD group, 6 (38%) were female, and the mean (SD) age was 22.43 (4.95) years; of 17 in the placebo group, 10 (59%) were female, and the mean (SD) age was 25.35 (5.24) years; and of 19 in the control group, 8 (42%) were female, and the mean (SD) age was 23.89 (4.14) years. Brain activation (indexed using the median sum of squares ratio of the blood oxygen level–dependent hemodynamic response effects model component to the residual sum of squares) was analyzed in 15 participants in the CBD group, 16 in the placebo group, and 19 in the control group.

    Participants receiving placebo had reduced activation relative to controls in the right caudate during encoding (placebo: median, −0.027; interquartile range [IQR], −0.041 to −0.016; control: median, 0.020; IQR, −0.022 to 0.056; P < .001) and in the parahippocampal gyrus and midbrain during recall (placebo: median, 0.002; IQR, −0.016 to 0.010; control: median, 0.035; IQR, 0.015 to 0.039; P < .001). Within these 3 regions, activation in the CBD group was greater than in the placebo group but lower than in the control group (parahippocampal gyrus/midbrain: CBD: median, −0.013; IQR, −0.027 to 0.002; placebo: median, −0.007; IQR, −0.019 to 0.008; control: median, 0.034; IQR, 0.005 to 0.059); the level of activation in the CBD group was thus intermediate to that in the other 2 groups. There were no significant group differences in task performance.

    Conclusions and Relevance  Cannabidiol may partially normalize alterations in parahippocampal, striatal, and midbrain function associated with the CHR state. As these regions are critical to the pathophysiology of psychosis, the influence of CBD at these sites could underlie its therapeutic effects on psychotic symptoms.

  2. These people are almost experts on this subject.
    Front Pharmacol. 2017 May 23;8:269. doi: 10.3389/fphar.2017.00269. eCollection 2017
    Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.  Campos AC1, Fogaça MV1, Scarante FF1, Joca SRL2, Sales AJ2, Gomes FV3, Sonego AB1, Rodrigues NS1, Galve-Roperh I4,5, Guimarães FS1.

    Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia.

    More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.

    Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. ECollection 2017            

    In Vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.  Watt G1, Karl T2

    Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do not stop or reverse the disease progression, highlighting the need for new, more effective therapeutics. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for AD. Here, we summarize the current status quo of in vivo effects of CBD in established pharmacological and transgenic animal models for AD.

    The studies demonstrate the ability of CBD to reduce reactive gliosis and the neuroinflammatory response as well as to promote neurogenesis. Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. Interestingly, combination therapies of CBD and Δ9-tetrahydrocannabinol (THC), the main active ingredient of cannabis sativa, show that CBD can antagonize the psychoactive effects associated with THC and possibly mediate greater therapeutic benefits than either phytocannabinoid alone. The studies provide "proof of principle" that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies. Further investigations should address the long-term potential of CBD and evaluate mechanisms involved in the therapeutic effects described.

  3. When the Bill of Rights is honored in this country, we can grow marijuana under freedom of religion across all 50 states. Neither the Constitution nor the Bill of Rights is honored in this country. Fake news CNBC is however a bunch of smoke and mirrors.

  4. I work in the industrial hemp industry, not CBD but I know many executives in CBD. The sector is full of scammers and fake numbers its' not nearly as big of an industry as they make it appear in the media and such. A few commenters are correct knowing THC activates the CBD to its full potential essentially. Most CBD oils in the market are bullshit and I know for a fact because I know the people, that the testing facilities take bribes and put down whatever you want on the label. Fiber hemp will be the future very soon and most of the hemp industry money will go into products derived from fiber varieties not CBD or other cannabinoids like CBG that are currently coming up. The hemp industry in many ways is a joke and most of the CEO's and executives in the companies are felons and have no experience running a business, this is why epidolex, the FDA approved CBD medication for epilepsy took the medical field first. A bunch of clowns were trying to figure out how to get an FDA approved oil and the pharma/biotech industry made it happen within a year beating everyone else to market. I know sooo many CBD isolate or oil suppliers who can't even offload their product as well theres an immense issue with CBD going to waste. Most of CBD is basically snake oil or if it's actually CBD there's no evidence to prove their product has any actual benefits. Hemp will be the future in many ways but not CBD.

  5. Most growers in NorCal believe Cbd is useless without thc to activate it. Snake oil by itself, they won’t let us test
    America is so evil a nation they won’t allow freedom for a healing plant. Wow

Leave a Reply

Your email address will not be published.